Successful therapy of cutaneous Tcell lymphoma

References

• Heald P, Latkowski JA. Cutaneous T-cell lymphomas. In: Fitzpatrick’s Dermatology in General Medicine . Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI (Eds). McGraw Hill Publishers, NY, USA 1537–1557 (2003).
   Google Scholar
• Heald P. Clinical trials and efficacy assessment in the therapy of cutaneous T cell lymphoma. Ann. NY Acad. Sci.941, 155–165 (2001).
   PubMed Web of Science ®Google Scholar
• Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch. Dermatol.134, 949–954 (1998).
   PubMed Web of Science ®Google Scholar
• Heald P, Mehlmauer M, Martin AG, Crowley CA, Yocum RC, Reich SD. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the Phase III clinical trial. J. Am. Acad. Dermatol.49(5), 801–815 (2003).
   PubMed Web of Science ®Google Scholar
• Zackheim HS, Epstein EH, Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J. Am. Acad. Dermatol.22, 802–810 (1990) .
   PubMed Web of Science ®Google Scholar
• Zackheim HS, Epstein E, McNutt NA, Grekin DA, Crain WR. Topical carmustine for mycosis fungoides and related disorders: a 10 year experience. J. Am. Acad. Dermatol.9, 363–372 (1983).
   Google Scholar
• Vonderheid EC, Tan ET, Cantor AF, Shrager L, Micaily B, Van Scott, EJ. Long term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy and cutaneous T-cell lymphoma. J. Am. Acad. Dermatol.20, 416–428 (1989).
   PubMed Web of Science ®Google Scholar
• Vonderheid EC, Van Scott EJ, Wallner PE et al. A 10 year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy. Cancer Treat. Rep.63, 681–689 (1979).
   PubMedGoogle Scholar
• Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoides. J. Am. Acad. Dermatol.19, 684–691 (1988).
   PubMed Web of Science ®Google Scholar
• Lee LA, Fritz KA, Golitz L et al. Second cutaneous malignancies in patients with mycosis fungoides treated with topical nitrogen mustard. J. Am. Acad. Dermatol.7, 590–598 (1982).
   Google Scholar
• Price NM, Hoppe RT, Deneau G. Ointment based mechlorethamine treatment for mycosis fungoides. Cancer52, 2214–2219 (1983).
   Google Scholar
• Diederen PV, Van Weelden H, Sanders CJ, Van Vloten WA. Narrowband UVB and psoralen-UVA in the treatment of early stage mycosis fungoides: a retrospective study. J. Am. Acad. Dermatol.48, 215–219 (2003).
   PubMed Web of Science ®Google Scholar
• Herrmann JJ, Roenigk HH Jr, Hurria A et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J. Am. Acad. Dermatol.33, 234–242 (1995).
   PubMed Web of Science ®Google Scholar
• Mostow EN, Neckel SL, Oberhelman L, Anderson TF, Cooper KD. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon α and PUVA. Arch. Dermatol.129, 747–762 (1993).
   Google Scholar
• Singh F, Lebwohl MF. Cutaneous T cell lymphoma treatment using bexarotene and PUVA: a case series. J. Am. Acad. Dermatol.51, 570–573 (2004).
   PubMed Web of Science ®Google Scholar
• Abel EA, Sendagorta E, Hoppe RT Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoides. J. Am. Acad. Dermatol.14, 1029–1038 (1986).
   PubMed Web of Science ®Google Scholar
• Swanbeck G, Roupe G, Sandstrom MH. Indication of a considerable decrease in the death rate in mycosis fungoides by PUVA therapy. Acta Derm. Venereol.74, 465–466 (1994).
   PubMed Web of Science ®Google Scholar
• Roupe G, Sandstrom MH, Kjellstrom C. PUVA in early mycosis fungoides may give long-term remission and delay extracutaneous spread. Acta Derm. Venereol.76, 475–478 (1996).
   Google Scholar
• Ramsay DL, Lish KM, Yalowitz CB, Soter NA. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch. Dermatol.128, 931–933 (1992).
   PubMed Web of Science ®Google Scholar
• Hofer A, Cerroni L, Kerl H, Wolf P. Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch. Dermatol.135, 1377–1380 (1999).
   PubMed Web of Science ®Google Scholar
• Resnik KS, Vonderheid EC. Home UV phototherapy of early mycosis fungoides: long-term follow-up observations in thirty-one patients. J. Am. Acad. Dermatol.29, 73–77 (1993).
   Google Scholar
• Wilson LD, Kacinski BM, Jones GW. Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (mycosis fungoides). Int. J. Radiat. Oncol. Biol. Phys.40, 109–115 (1998).
   PubMed Web of Science ®Google Scholar
• Jones G, Wilson LD, Fox-Goguen L. Total skin electron beam radiotherapy for patients who have mycosis fungoides. Hematol. Oncol. Clin. North Am.17, 1421–1434 (2003).
   Google Scholar
• Wilson LD, Quiros PA, Kolenik SA et al. Additional courses of total skin electron beam therapy in the retreatment of patients with cutaneous T-cell lymphoma. J. Am. Acad. Dermatol.35, 69–73 (1996).
   PubMed Web of Science ®Google Scholar
• Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational Phase II–III trial results. J. Clin. Oncol.19, 2456–2471 (2001).
   PubMed Web of Science ®Google Scholar
• Duvic M, Martin AG, Kim Y et al. Phase 2–3 clinical trial of oral Targretin (bexarotene) capsules for the treatment of refractory or persistent early stage cutaneous T-cell lymphoma. Arch. Dermatol.137, 581–593 (2001).
   PubMed Web of Science ®Google Scholar
• Sherman SI, Gopal J, Haugen BR et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N. Engl. J. Med.340, 1075–1079 (1999).
   PubMed Web of Science ®Google Scholar
• McGinnis KS, Junkins-Hopkins JM, Crawford G et al. Low-dose bexarotene in combination with low-dose interferon α in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J. Am. Acad. Dermatol.50, 375–379 (2004).
   PubMed Web of Science ®Google Scholar
• Talpur R, Duvic M. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene. Clin. Lymph. Myel.6, 488–492 (2006).
   PubMedGoogle Scholar
• Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat for refractory cutaneous T-cell lymphoma. Blood109, 31–39 (2007).
   PubMed Web of Science ®Google Scholar
• Edelson RL, Berger CL, Gasparro FS et al. Treatment of cutaneous T cell lymphoma with extracorporeal photochemotherapy. N. Engl. J. Med.316, 297–303 (1987).
   PubMed Web of Science ®Google Scholar
• Heald PW, Rook A, Perez M et al. Treatment of erythrodermic cutaneous T-cell lymphoma patients with photopheresis. J. Am. Acad. Dermatol.27, 427–433 (1992).
   PubMed Web of Science ®Google Scholar
• Bunn PA, Foon KA, Ihde DC et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann. Intern. Med.101, 484–487 (1984).
   PubMed Web of Science ®Google Scholar
• Dreno B, Godefroy WY, Fleischmann M et al. Low-dose recombinant interferon-α in the treatment of cutaneous T-cell lymphoma. Br. J. Dermatol.121, 543–544 (1989).
   Google Scholar
• Kohn EC, Steis RG, Sausville EA et al. Phase II trial of intermittent high-dose recombinant interferon α-2a in mycosis fungoides and the Sezary syndrome. J. Clin. Oncol.8, 155–160 (1990).
   PubMed Web of Science ®Google Scholar
• Olsen EA, Rosen ST, Vollmer RT et al. Interferon α-2A in the treatment of cutaneous T-cell lymphomas. J. Am. Acad. Dermatol.20, 395–407 (1989).
   PubMed Web of Science ®Google Scholar
• Molina A, Zain J, Arber DA et al. Durable clinical, cytogenetic and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J. Clin. Oncol.23, 6163–6171 (2005).
   PubMed Web of Science ®Google Scholar
• Herbert KE, Spencer A, Grigg A, Ryan G, McCormack C, Prince HM. Graft versus lymphoma effect in refractory cutaneous T cell lymphoma after reduced intensity HLA matched sibling allogeneic stem cell transplantation. Bone Marrow Trans.34, 521–525 (2004).
   PubMed Web of Science ®Google Scholar
• Foss FM, Borkowski TA, Gilliom M et al. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a Phase II study. Blood84, 1765–1774 (1994).
   PubMed Web of Science ®Google Scholar
• Olsen E, Duvic M, Frankel A et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol.19(2), 376–388 (2001).
   PubMed Web of Science ®Google Scholar
• Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel T. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin. Lymphoma1, 298–302 (2001).
   PubMedGoogle Scholar
• Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J. Am. Acad. Dermatol.49, 873–878 (2003).
   PubMed Web of Science ®Google Scholar
• Lybaek D, Iversen L. Pegylated liposomal doxorubicin in the treatment of mycosis fungoides. Acta Derm. Venereol.86, 545–547 (2006).
   Google Scholar
• Wollina U, Dummer R, Brockmeyer NH et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer98, 993–1001 (2003).
   PubMed Web of Science ®Google Scholar